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Background: Mismatch repair (MMR) genes are known to be frequently altered in colorectal cancer (CRC). Both
genetics and epigenetics modifications seems to be relevant in this phenomenon, however it is still not clear how
these two aspects are interconnected. The present study aimed at characterizing of epigenetic and gene expression
profiles of MMR genes in sporadic CRC patients from the Czech Republic, a country with one of the highest
incidences of this cancer all over Europe.
Methods: Expression levels and CpG promoter methylation status of all MMR genes were evaluated in DNA from
tumor and adjacent mucosal samples of 53 incident CRC patients.
Results: We have found significantly increased transcription levels in EXO1 gene in tumor tissues (P = 0.05) and
significant over-expression of MSH3 gene in colon tumors when compared to adjacent mucosal tissues (P = 0.02).
Interestingly, almost all MMR genes were differently expressed when localization of tumors was compared. In particular,
colon tumors showed an up-regulation of EXO1, MSH2, MSH3, MSH6, and PMS2 genes in comparison to rectal tumors
(P = 0.02). Expression levels of all MMR genes positively correlated between each other. The promoter methylation of
MLH1 gene was observed in 9% of CRC tissues only.
Conclusions: In our study, we have observed different pattern of MMR genes expression according to tumor localization.
However, a lack of association between methylation in MMR genes and their corresponding expressions was noticed
in this study, the relationship between these two aspects is worthy to be analyzed in larger population studies and in
pre-malignant stages.
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Colorectal cancer (CRC) represents a serious health
problem in the Central Europe and particularly in the
Czech Republic, where the incidence for colon and rec-
tal cancers ranks the third and the first highest world-
wide, respectively [1,2]. Notably, rates among males in
the Czech Republic and Japan have already exceeded the
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distribution, and reproduction in any mediumand Australia, where rates are declining or stabilizing
[3,4]. The reasons for such frequencies are unknown. It
is generally accepted that the etiology of CRC is multi-
factorial, involving hereditary and environmental factors,
as well as somatic changes occurring during tumor pro-
gression [5].
There are at least three distinct, and relatively discrete,
molecular pathways associated with this disease: chromo-
somal instability (CIN), microsatellite instability (MSI) and
the cytosine phosphate guanine (CpG) island methylator
phenotype (CIMP). The development of MSI pathway (15%
of CRC) is considered to be due to defective DNA mis-
match repair (MMR) system [6]. In CIMP, a number ofntral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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thylation of their promoters, and this represents a key epi-
genetic mechanism of inactivation of tumor suppressor
genes [7], as well as MMR genes. Impaired MMR system,
arising frequently from aberrant methylation of gene pro-
moters, may be detectable by an altered gene and protein
expression patterns. Aberrant DNA methylation - hyper-
methylation and hypomethylation compared to normal
tissue - has been associated with a large number of human
malignancies, including CRC [8]. DNA hypomethylation,
prevalent as a genome-wide event, usually occurs in more
advanced stages of tumor development whereas DNA
hypermethylation is often observed as a discrete, targeted
event within tumor cells, resulting in specific loss of gene
expression [9].
Based on a number of relatively large case–control and
prospective cohort studies, ∼30–40% of sporadic proximal-
site colon cancers are CIMP positive, compared to 3–12%
of distal colon and rectal cancers [10,11]. Thus, CIMP is at-
tributable to tumors of the proximal colon, independently
of MSI status. CIMP has been also associated with BRAF
mutations in both microsatellite stable and unstable colon
cancers [11,12]. It has been suggested that there are two
general types of CIMP in sporadic tumors: CIMP high, re-
lated to BRAF mutations and MLH1 methylation, and
CIMP low, related to KRAS mutations [13].
Approximately 90% of all MMR alterations/modifications
in sporadic CRC cases are most commonly caused by epi-
genetic inactivation of MLH1 or MSH2 gene [14]. The
hypermethylation of the MLH1 promoter is also the pre-
dominant cause of MSI high (MSI-H) in sporadic tumors
[15]. MSI-H cancers with methylated MLH1 are distinct
from the rest of CRC by delayed onset and association with
the female gender [16]. On the other hand, CRC cases
without altered MMR genes show low-frequency MSI
(MSI-L) or are microsatellite stable (MSS) [14]. Moreover,
gene alterations of other MMR genes may also be involved
in the CRC progression [17]. Goel et al. [18] assumed that
germline hypermethylation of MLH1 and MSH2 may serve
as predisposing events in some CRC cases.
The Czech Republic has one of the highest reported inci-
dences of CRC worldwide, thus the analysis of mRNA
expression profile of MMR genes and their epigenetic
characterization has a great meaning. Apparently, the clari-
fication of a potentially abnormal epigenetic profile of
tumor tissues, as well as their genetic constitution, could
contribute to better classify the CRC cases or could ultim-
ately result in the improvement of therapy.
Thus the aim of our study was to investigate the epi-
genetic characteristics and gene expression profiling of
MMR genes in tumors of CRC patients of Czech nation-
ality, with respect to their clinical and histopathological
characteristics. We have hypothesized that the high inci-
dence of CRC in this country could be due to differentgenetic and epigenetic pattern of DNA repair genes,
which could reflect possible specific geographical, ethnic,
dietary or lifestyle factors.
Methods
Patients’ characteristics and collection of biological
specimen
Fifty three patients with sporadic CRC were recruited be-
tween 2009 and 2011 at the Thomayer Hospital and at the
General University Hospital (both located in Prague, Czech
Republic), where they underwent surgical resection. All pa-
tients signed an informed consent. Ethics approval was
granted by the committees of the above hospitals.
From each patient, tumor tissue and adjacent mucosal
colon/rectal tissue (5–10 cm distant from the tumor) were
resected and deep frozen immediately after removal. Per-
ipheral blood was taken a day before surgery and stored at
4°C until processing that was no longer than 3 hours. The
clinical stage of patients at diagnosis was classified accord-
ing to the tumor–node–metastasis (TNM) system accord-
ing to UICC (Union for International Cancer Control).
Tumor and adjacent mucosal tissues were homoge-
nized by MagNA Lyser (Hoffmann-La Roche). Genomic
DNA and mRNA were isolated from tumor tissues and
adjacent mucosal tissue with AllPrep DNA/RNA Isolation
Kit protocol according to the manufacturer’s instructions
(Qiagen, Hilden, Germany).
MSI status
MSI was assessed by multiplex PCR with pseudomono-
morphic mononucleotide markers BAT-25, BAT-26, NR-
21, NR-24, NR-27 using primers labeled with FAM, HEX,
or NED followed by analysis of PCR products on 5% de-
naturing gel electrophoresis on ABI PRISM 310 System
(Applied Biosystems) as described previously by [19].
Tumor DNA samples were compared, and tumors
showing instability at one or two locus were scored as
MSI-low (MSI-L), at three or more loci as MSI-high
(MSI-H). Genescan software was used for calculation of
the size of each fluorescent PCR product.
Gene expression profiling
Gene selection
A panel of all MMR genes was extracted from the
complete list of all DNA repair genes organized by
pathways available online (http://sciencepark.mdanderson.
org/labs/wood/DNA_Repair_Genes.html#MMR). Eleven
genes (EXO1, MLH1, MLH3, MSH2, MSH3, MSH4, MSH5,
MSH6, PMS1, PMS2, and PMS2L3) were analyzed for
mRNA expression levels.
Sample preparation
The total RNA was measured on ASP-3700 UV/Vis
Spectrophotometer (Avans-Biotechnology, Taiwan) for
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of nucleic acid purity. RNA integrity number (RIN)
was checked using Agilent Bioanalyzer 2100, with RNA
6000 Nano Assay (Agilent Technologies). Each pair of
tumor/adjacent mucosal tissue did not differ by more than
±2 RIN units. The complementary DNA (cDNA) was ob-
tained from 1 μg of total RNA by using First strand cDNA
synthesis kit (MBI Fermentas, Vilnius, Lithuania). All sam-
ples were tested to exclude possible inhibition of the quan-
titative PCR (qPCR) reaction by spiking with RNA from an
extraction control kit (TATAA, Sweden). cDNA was diluted
to 10 ng/mL and preamplified for 18 cycles on a Bio-Rad
CFX96 Real Time PCR Instrument (Bio-Rad) with TaqMan
Preamp Master Mix (Applied Biosystems) according to the
manufacturer’s protocol. qPCR was conducted using the
high-throughput platform BioMark HD System (Fluidigm).
Five μL of Fluidigm sample premix consisted of 1 μL
of 20× diluted preamplified cDNA, 0.25 μL of 20×Gene
Expression (GE) sample loading reagent (Fluidigm), 2.5 μL
of TaqMan universal mastermix II without uracil-N glyco-
slyase (UNG; Life Technologies), and 1.25 μL of RNase/
DNase-free water. Each sample premix was combined with
5 μL FAM-MGB assays (Primer Design) at a final concen-
tration of 300 nmol/L and 2.5 μL 2x Assay loading reagent
(Fluidigm). The reaction volume for a single qPCR reaction
was 6.7 nL. Thermal conditions for qPCR were: 95°C for
10 minutes, 45 cycles of 95°C for 15 seconds, and 60°C
for 60 seconds. Actin beta (ACTB) and 18S rRNA were
used as reference genes selected from a geNorm reference
genes selection kit (Primer Design) by Normfinder (GenEx
Enterprise).
qPCR data pre-processing
Data were collected from 2 GE Dynamic Arrays 96.96
(Fluidigm) and pre-processed in GenEx Enterprise software
(MultiD). Interplate calibration was conducted and the
technical replicates were averaged. Cut-off value for Cq was
set at 25. The Cq 25 measured in BioMark system would
approximately correspond to Cq 35 at the conventional
qPCR cyclers [20]. When more than 12% of the data were
missing for each sample/gene due to a very low expression
and low fluorescence signal, the particular sample/gene was
removed from the dataset. As a result of this selection
MSH4, MSH5 and PMS2L3 genes were excluded from ana-
lyses. Data were normalized to reference genes, recalculated
to relative quantities with the lowest expression set to 1,
and transformed to log2 scale.
Promoter CpG islands methylation profiling
Methylation-specific PCR
A prediction of CpG islands site within the promoter
region of MMR genes was carried out by screening
with CpG Islands Searcher (http://cpgislands.usc.edu/).
Genomic DNA was treated with sodium bisulfite usingthe Epitect Whole Bisulfitome Kit (Qiagen, Hilden,
Germany). Methylation-specific PCR (MSP) analysis of
bisulfite-converted DNA was conducted using the Epitect
MSP kit (Qiagen, Hilden, Germany), following the pro-
ducer’s protocols. Primers (Sigma-Aldrich; Additional file
1: Table S1a) specific for methylated and unmethylated
bisulfite-converted DNA were designed for investigated
genes by applying MethPrimer algorithm [21]. To test
whether promoter methylation can affect the mRNA ex-
pression levels of MMR genes, only those genes which
were successfully analyzed for the gene expression were
subsequently considered. MSP reactions were performed
as previously described by [22].Methylation-sensitive high resolution melting
Methylation-sensitive high resolution melting (MS-HRM)
was conducted only on those samples that showed posi-
tive results in MSP, to validate the observations. Whole
genomic DNA was treated with sodium bisulfite using the
Epitect Bisulfite Kit (Qiagen, Hilden, Germany) to convert
unmethylated cytosines to uracils, following the manufac-
turer’s protocol, as described in [23]. Real-time PCR
followed by HRM was carried out in high-performance
Eco Real-Time PCR system (Illumina, San Diego, CA,
USA). Primer sequences for MLH1 were described earlier
[23,24], while for MLH3 primers (Additional file 1: Table
S1b) were designed using Methyl Primer Express Software
v1.0 (Applied Biosystems, Foster City, CA, USA). The re-
action mixture (10 μl final volume) consisted of 10 ng of
template DNA, 1× EpiTect HRM Master Mix (Qiagen)
and 300 nmol/l of each primers. PCR was initiated by in-
cubation at 95°C for 5 min, followed by 50 cycles at 95°C
for 10 sec, 56°C for 20 sec, 72°C for 10 sec. For each assay,
a standard dilution series of EpiTect Control DNAs
(Qiagen) was run to assess the quantitative properties and
sensitivity of the assay. Fluorescence data were converted
into melting peaks by the Eco Software (Illumina, Ver.
3.0.16.0). The cut-off value for aberrant methylation was
set to 25% or higher.Statistical analyses
Statistical analyses were conducted by IBM SPSS
Statistics 18, GenEx Enterprise and SAS 9.2 software.
Expression levels of all studied genes did not follow a
normal distribution in the study population, as ana-
lyzed by Kolmogorov–Smirnov test. Data were loga-
rithmically transformed and nonparametric tests were
used for statistical analyses; for comparison of me-
dians, Mann–Whitney test was applied. Correlations
were determined by a Spearmen correlation coefficient.
All statistical tests were conducted at a 95% confidence
level.
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Population characteristics
The detailed patient’s characteristics are shown in
Table 1. The study group included 38 men and 15
women with a mean age of 67.0 (±10.6) years. Twenty
six patients had a tumor localized in the colon and 27
in the rectum. Seven patients were diagnosed with
pathologic stage I, 27 with stage II, 11 with stage III
and 8 with stage IV. All tumors were histologically
confirmed as adenocarcinomas. Three patients had
tumor of a well-differentiated grade, 43 a moderately
differentiated and 7 patients poorly differentiated.
Ten patients with rectal cancer received neoadjuvant
therapy before surgery.MSI status
Tumor tissue of 6 patients displayed MSI. For all of
them, 3 and more loci showed nucleotide expansions
and they were therefore considered to be MSI-H. All six
patients were diagnosed for colon cancer. No association
of MSI status with gender, age, TNM and grade was





Age at diagnosis (years)
Mean ± SD 67.0 ±10.6
Diagnosis
Colon cancer 26 (49.1)








Moderately differentiated 43 (81.1)




MSI status in colon cancer
Proximal colon 5 (83.3)
Distal colon 1 (16.7)Expression of MMR genes
Expression levels of 8 MMR genes were successfully an-
alyzed (Figure 1, Additional file 1: Table S2). Three other
MMR genes (MSH4, MSH5 and PMS2L3) were excluded
from final analyses due to a very low expression and low
fluorescence signal.
Overall, only EXO1 was differentially expressed in our
study group: significantly higher mRNA levels were ob-
served in tumor tissues when compared with adjacent
mucosal tissue (1.16-fold; P = 0.048; Figure 1).
After stratifying patients according to the tumor
localization, a different pattern for colon and for rectal
carcinomas was observed. Specifically, significantly higher
expression levels of MSH3 gene were observed in colon tu-
mors when compared to adjacent mucosal tissue (1.18 fold
change, P = 0.02; Additional file 1: Table S3b). No differ-
ences in gene expression were observed in rectal tumors
when compared to adjacent mucosal tissues.
Interestingly, when expression levels of only tumor tis-
sues with different localization were compared, tumor
localized in colon showed significantly increased levels of
almost all analyzed MMR genes, namely MSH2 (1.68, P <
0.0001), MSH3 (1.27, P = 0.001), MSH6 (1.43, P = 0.004),
PMS2 (1.16, P = 0.005) and EXO1 (1.30 fold change, P =
0.02) (Figure 2; Additional file 1: Table S3a). Although less
robust, the same tendency was also observed in the adja-
cent mucosal tissue for MSH2 (1.65 fold change, P = 0.02)
and PMS2 (1.18, P = 0.03) genes. Further stratification for
left and right colon did not show any differences (data not
shown).
The expression pattern of investigated MMR genes
was irrespective of other clinical features (pTNM staging
and tumor differentiation). The only exception was for
PMS2 gene in colon tumors, where patients with the
pTNM stage I + II had significantly lower expression
levels than those with pTNM III + IV (−1.13, P = 0.01;
data not shown). No difference was observed when pa-
tients were stratified for any of the considered demo-
graphic factors (e.g. age, sex).
Ten patients with rectal cancer (18.9%) received neo-
adjuvant therapy before surgery. However, none of the
analyzed genes differed in the expression levels among
rectal cancer patients irrespectively of the neoadjuvant
therapy.
Relationships of expression levels among different
MMR genes
MMR genes positively correlated between each other in
both tumor and adjacent mucosal tissues (Tables 2 and 3).
The most pronounced significant correlations in tumors
were observed between MLH3 and PMS1 or PMS2 (R =
0.822 and R = 0.903, P < 0.0001 for both); between MSH2
and MSH6 (R = 0.854, P < 0.0001), and both PMS1 and
PMS2 (R = 0.835, P < 0.0001) (Table 2).
Figure 1 mRNA expression levels of MMR genes in tumor and adjacent mucosal tissues in the study subjects, expressed as quantities
relative to the lowest detected expression assigned as value 1.
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MLH3 correlated with PMS1 and PMS2 (R = 0.887 and R =
0.931, P < 0.000, respectively), but, additionally, MLH3 also
correlated with MSH6 (R = 0.857, P < 0.0001). In addition,
MSH2 again correlated with MSH6 (R = 0.880, P < 0.0001)
and PMS1 and PMS2 (R = 0.855, P < 0.0001). Concerning
the EXO1, in adjacent mucosal tissue the gene strongly cor-
related with MLH3, MSH6 and PMS1 (R = 0.849, R = 0.849,
and R = 0.814, P < 0.0001 for all) (Table 3).Figure 2 mRNA expression levels of MMR genes in colon and rectum
expression assigned as value 1.Promoter methylation of MMR genes
The promoter methylation status was analyzed only in
those genes whose expression analyses were successfully
conducted. Therefore, methylation levels of promoter re-
gions of EXO1, MLH1, MLH3, PMS1, PMS2, MSH2,
MSH3, and MSH6 genes were evaluated in DNA from
tumor and adjacent mucosal tissues of 53 CRC patients.
Methylation of promoter region was detected only in
MLH1 (Additional file 2: Figure S1). For this gene, atumors, expressed as quantities relative to the lowest detected
Table 2 Correlations between mismatch repair genes in tumor tissues
Gene Exo1 Mlh1 Mlh3 Msh2 Msh3 Msh6 Pms1 Pms2
Exo1 1
Mlh1 0.244 (0.115) 1
Mlh3 0.721 (0.000) 0.395 (0.009) 1
Msh2 0.577 (0.000) 0.285 (0.064) 0.601 (0.000) 1
Msh3 0.125 (0.423) 0.495 (0.001) 0.268 (0.082) 0.478 (0.001) 1
Msh6 0.648 (0.000) 0.177 (0.257) 0.695 (0.000) 0.854 (0.000) 0.247 (0.110) 1
Pms1 0.711 (0.000) 0.368 (0.015) 0.822 (0.000) 0.593 (0.000) 0.191 (0.220) 0.670 (0.000) 1
Pms2 0.783 (0.000) 0.381 (0.012) 0.903 (0.000) 0.745 (0.000) 0.342 (0.025) 0.784 (0.000) 0.835 (0.000) 1
R and P value (in brackets), Significant differences are in bold, differences significant after Dunn–Bonferroni correction (P < 0.0032) are in italics.
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analyzed. Five tumors and two samples from adjacent
mucosal tissues exhibited methylated MLH1 promoter re-
gion. In patients, where normal tissues presented MLH1
promoter methylation, tumor tissue also exhibited pro-
moter methylation.
The investigated promoter region resulted methylated
in MSI-H colon tumors only (p < 0.00001).
We did not observe any statistical significant variation
in mRNA expression levels of MLH1 gene in the pa-
tients with promoter methylation when compared to
patients without promoter methylation.
Discussion
Genetic and epigenetic alterations underlie the patho-
genesis of cancer. In particular, the disruption of epi-
genetic mechanisms leads to abnormal development of
cells and is involved in malignant transformation [25].
Variations in DNA methylation are important epigen-
etic modifications which may affect gene expression by
modifying the DNA structure without altering the na-
tive nucleotide sequence.
In the present study, we have analyzed the mRNA ex-
pression of MMR genes and their promoter methylation
in CRC tissues in patients from the Czech Republic, a
country that has the second highest CRC incidence and
mortality among 38 European countries [1]. With the
exception of MLH1 and MSH2 genes, the methylationTable 3 Correlations between mismatch repair genes in adjac
Gene Exo1 Mlh1 Mlh3 Msh
Exo1 1
Mlh1 0.323 (0.035) 1
Mlh3 0.849 (0.000) 0.362 (0.017) 1
Msh2 0.758 (0.000) 0.230 (0.139) 0.715 (0.000) 1
Msh3 0.046 (0.771) 0.511 (0.000) 0.166 (0.289) 0.281 (0
Msh6 0.849 (0.000) 0.230 (0.192) 0.857 (0.000) 0.880 (0
Pms1 0.814 (0.000) 0.399 (0.008) 0.887 (0.000) 0.630 (0
Pms2 0.793 (0.000) 0.367 (0.016) 0.931 (0.000) 0.658 (0
R and P value (in brackets), Significant differences are in bold, differences significanstatus of the other MMR genes was globally less studied
or even never previously analyzed.
In our study, we observed the promoter methylation
of MLH1 gene only. Notably, this modification was ob-
served in MSI-H colon tumors only, as it is generally ob-
served in CRC [14]. The incidence of MLH1 promoter
methylation observed in our study is in concordance
with another Czech study of Vasovcak et al. [26], where
mutational profiles of CRC high risk genes together with
methylation of MLH1 gene were analyzed. Similarly to
the work of Vasovcak et al. [26], any MLH1 promoter
methylation was not detected in rectal tumors. Rare
MLH1 promoter methylation in rectal cancers was de-
scribed also in the study of Samowitz et al. [27], but it
was accompanied by high degree of MMR protein defi-
ciency, possibly due to the inclusion of Lynch associated
tumors. The reason for the differential MLH1 promoter
methylation and tumor localization is still unknown and
can be caused by dietary habits, different environment
(e.g. varying pH) in different parts of the colon, or by
the combination of both aspects [26] or by other factors
which could affect the presence of promoter methyla-
tion, like presence of bacterial flora [28]. In our study,
the presence of promoter methylation of MLH1 gene
was also not related to the mRNA levels. This lack of as-
sociation could be due to the small size of the popula-
tion. An inverse correlation to MLH1 expression was
observed in a previous study of Oster et al. [24] and mayent mucosal tissues
2 Msh3 Msh6 Pms1 Pms2
.068) 1
.000) 0.054 (0.731) 1
.000) 0.100 (0.525) 0.769 (0.000) 1
.000) 0.135 (0.390) 0.782 (0.000) 0.855 (0.000) 1
t after Dunn–Bonferroni correction (P < 0.0032) are in italics.
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might be explained by the fact that only few CpG sites
were interrogated, and the interrogated sites may not be
the sites involved in regulation of the gene. In addition,
the presence of alternative transcription start sites may
also be involved. Recently Jones [29] summarized that
genes silenced by Polycomb complexes are much more
likely than other genes to become methylated in cancer
and thus a silent state could even precede methylation.
Thus, the evidence regarding the timing of DNA
methylation could be consistent with the idea that
methylation adds an additional level of stability to epi-
genetic states.
In patients where the tumor and normal tissues pre-
sented MLH1 promoter methylation, blood samples were
also analyzed to confirm potential germline hypermethyla-
tion. However, in our study, we did not observe any MLH1
promoter methylation in the DNA from blood (data not
shown). This result pointed to somatic origin of MLH1
promoter methylation in our study.
Although rather small (1.16-fold), we also observed differ-
ent expression levels for EXO1 gene when compared tumor
and adjacent mucosal tissues. Higher expression levels for
EXO1 in tumor tissues are in agreement with the study of
Ioana et al. [30]. Although, data in that study were normal-
ized to a different reference gene, GAPDH, and the investi-
gated population was also smaller than ours. Recently,
Caradec et al. [31] suggested not to use GAPDH as a refer-
ence gene for normalization in CRC experiments, since it
appears to be among the most variable. Other authors
showed that GAPDH expression varies according to oxygen
tension and hypoxia, critical factors in cancer development,
especially in CRC [32]. On the other hand, Ide et al. [33]
observed a lower mRNA level of MMR genes in tumor
samples as compared with the normal tissue. In our study,
MSH3 gene had significantly higher expression levels in
colon tumors when compared to adjacent mucosa. Tentori
et al. [34] observed that defective expression of the protein
MSH3 is frequently detected in colon cancer. Higher ex-
pression levels were found in tumors of the colon when
compared to those in the rectum. These differences were
more pronounced in EXO1, MSH2, MSH3, MSH6, and
PMS2 genes. The same tendency was observed in adjacent
mucosa for MSH2 and PMS2 genes. Our results may sug-
gest different mechanisms in the genesis of colon and rectal
cancers as it was already postulated by [35]. The reason for
higher mRNA levels of MMR genes in colon could be actu-
ally due to the fact that stools are kept in the colon for a
longer time than in the rectum. In this way, colon is more
exposed to various carcinogens from the food, and thus
needs more protection against the carcinogenic events.
Higher expression levels of DNA repair genes could be one
of these mechanisms of protection. As tumor localization
was the major factor influencing gene expression, location-specific analysis may identify location-associated pathways
and enhance the accuracy of class prediction.
In the present study, we have also observed a strong rela-
tionship between between EXO1 expression and those of
genes involved in the MutSα heterodimer (MSH2-MSH6).
Previously, Jiricny [36] also noticed that decreased activity
of EXO1 is accompanied with the low concentrations of
genes involving in the MutSα heterodimer.
We observed a strong correlation between expressions
of MSH2 and MSH6 genes. Vageli et al. [37] recently
demonstrated that reduction of MSH6 mRNA levels is a
frequent event in bladder tumorigenesis and reflects
a common mechanism of suppression with MSH2. An-
other MMR heterodimer, MutLα, consisting of MLH1
and PMS2, positively correlated, but the strength of such
correlation was considerably lower than that for the
MutSα heterodimer. Interestingly, the strongest correla-
tions were observed between MLH3 and PMS1 and
PMS2. This is the first time that a correlation between
above genes is reported. Previous observations indicated
that PMS2 gene is required for the correction of single-
base mismatches, and PMS2 and MLH3 contribute both
to the correction of insertion-deletion loops resulting
from DNA replication, DNA damage or from recombin-
ation events between non-identical sequences during
meiosis [38]. The role of PMS1 in MMR still awaits fur-
ther clarification, but it is assumed that coordinates the
downstream processes after mismatch recognition by
MutSα heterodimer together with MLH1 [39].
DNA repair pathways are a part of a multistep, multi-
factorial process to remove the damaged DNA sequence
and to resynthesize particular part of the DNA strand.
Thus, interplay exerted by multiple genes is crucial and
more informative for identifying genes responsible for
human cancer. Analyzing the difference in expression,
individual variability, and co-expression in our study has
provided an initial characterization of the MMR pathway
and can help in further understanding of the cellular
DNA repair system in human CRC.
A lack of association between methylation in MMR genes
(representing rather low-frequency events) and their corre-
sponding expressions could be due to the small size of the
population. Above aspect emerges therefore as a main limi-
tation of the present study.
Conclusions
In summary, our combined genetic and epigenetic ana-
lysis confirmed some previous data from other studies
on CRC patients, but also provided novel findings. First,
a strong correlation was observed either between MLH3
and PMS1 or PMS2. Second, although we did not con-
firm the expected traits of deregulation of MMR genes
in sporadic CRC in patients recruited in the Czech Re-
public, we have found interesting and strong differences
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rectal tumors were compared. This finding might point
to the distinct genesis of both neoplasia. Outcomes of
the present study will require further validation with
functional assays, particularly in tumors and in larger
population study.
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